Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies

Commitments and Contingencies
6 Months Ended
Jun. 30, 2012
Commitments and Contingencies [Abstract]  


In connection with our acquisitions of CURNA, OPKO Diagnostics and FineTech, we agreed to pay future consideration upon the achievement of certain events. As a result, we recorded $20.1 million as contingent consideration, with $5.2 million recorded within Accrued expenses and $14.9 million recorded within Other long-term liabilities. Refer to Note 5.

In connection with the 2008 acquisition of Vidus Ocular, Inc. (“Vidus”), we agreed to issue additional stock consideration upon the occurrence of certain events including the issuance of 488,420 shares of our Common Stock upon the achievement of certain development milestones and, in the event that the stock price for our Common Stock at the time of receipt of approval or clearance by the FDA of a pre-market notification 510(k) relating to the Aquashunt™ is not at or above a specified price, we will be obligated to issue an additional 413,850 shares of our Common Stock.

We are a party to litigation in the ordinary course of business. We do not believe that any such litigation will have a material adverse effect on our business, financial condition, or results of operations.

We expect to incur substantial losses as we continue the development of our product candidates, continue our other research and development activities, and establish a sales and marketing infrastructure in anticipation of the commercialization of our diagnostic and pharmaceutical product candidates. We currently have limited commercialization capabilities and it is possible that we may never successfully commercialize any of our diagnostic and pharmaceutical product candidates. We do not currently generate revenue from any of our diagnostic and pharmaceutical product candidates. Our research and development activities are projected to expand over a period of time and will require further resources if we are to be successful in commercializing our product candidates. As a result, we believe that our operating losses are likely to be substantial over the next several years. We may need to obtain additional funds to further develop our research and development programs, and there can be no assurance that additional capital will be available to us on acceptable terms, or at all.